CDKN2B rs10811661 Variant: What the 9p21 Locus Means

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on Genetics & Metabolic Health. Browse all Genetics & Metabolic Health education

Few spots in the human genome have been studied as intensely as chromosome 9p21, and the CDKN2B gene sits at the heart of it. The variant rs10811661, located in the region near CDKN2A and CDKN2B, is one of the most reproducibly associated markers for type 2 diabetes in the world. If your results flag the rs10811661 genotype, it helps to understand what this locus does, what the evidence actually shows, and — just as important — what it does not mean for your health.

What CDKN2B does

CDKN2B encodes a protein called cyclin-dependent kinase inhibitor 2B (p15INK4b), which helps control the cell cycle — the process by which cells decide whether to grow and divide. Its neighbor CDKN2A encodes related cell-cycle brakes. In metabolic tissue, these genes influence how pancreatic beta cells — the cells that produce insulin — regenerate and maintain their numbers. That connection to beta-cell biology is the leading explanation for why this region is linked to blood sugar regulation.

The rs10811661 variant and type 2 diabetes

rs10811661 lies in a gene desert upstream of CDKN2A/CDKN2B, in a stretch of DNA that appears to regulate these genes rather than sit inside them. Large genome-wide association studies across many ancestries have tied genotypes at this position to differences in type 2 diabetes risk, with the effect thought to run through impaired beta-cell function and insulin secretion rather than insulin resistance.

Allele labels at this SNP can look confusing because reference strands differ between databases, which is why the same position is sometimes described by its C or T allele. What matters is the locus, not the letter: rs10811661 is a small, consistent statistical signal, not a switch that determines who develops diabetes.

The 9p21 region and cardiovascular biology

The same broad 9p21 region — through a separate nearby signal in the long non-coding RNA CDKN2B-AS1 (also called ANRIL) — has been independently linked to coronary artery disease. These are distinct association signals that happen to share a neighborhood, which is a reminder that a single genomic region can touch more than one pathway. It also underscores why cell-cycle and vascular biology are studied together in this part of the genome.

Why one variant is not destiny

Type 2 diabetes is polygenic and heavily shaped by environment. rs10811661 contributes a modest increment to inherited risk, and it sits alongside dozens of other variants and powerful lifestyle factors — body weight, physical activity, diet, and sleep. Two people with the same genotype can have very different metabolic health depending on those inputs. A risk-associated result is a prompt for awareness, not a prediction of disease.

Understanding your metabolic pathways

The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights spanning metabolism, appetite regulation, and related pathways. Reporting a variant like the one at CDKN2B is educational context about your predispositions — it does not diagnose diabetes, does not predict who will develop it, and is not a treatment plan. Interpretation of blood sugar and any clinical decisions belong with your healthcare provider.

The evidence-based path for metabolic health is well established and provider-guided: routine glucose or A1c screening when appropriate, physical activity, balanced nutrition, and weight management. Genetic insight helps you understand your starting point and engage those steps earlier and more intentionally.

Frequently Asked Questions

What does the CDKN2B rs10811661 variant mean?

rs10811661 is a genetic marker near the CDKN2A and CDKN2B genes on chromosome 9p21, strongly associated with type 2 diabetes risk in large studies. The effect is thought to work through pancreatic beta-cell function and insulin secretion, and it contributes only a small amount to overall risk.

Does carrying this variant mean I will get diabetes?

No. Type 2 diabetes is polygenic and heavily influenced by lifestyle. rs10811661 adds a modest increment to inherited risk, not a guarantee. Body weight, activity, diet, and dozens of other genes matter more collectively, so the variant is a prompt for awareness rather than a prediction.

Why is rs10811661 sometimes described by different alleles?

Genetic databases can report a variant using different reference strands, so the same position at rs10811661 is sometimes labeled by its C or T allele. What matters biologically is the locus near CDKN2A/CDKN2B and its statistical link to metabolic pathways, not the specific letter shown.

Can genetic testing diagnose diabetes?

No. Diabetes is diagnosed with blood tests such as fasting glucose or A1c, interpreted by a clinician. Genetic testing offers pathway-level context about metabolic predispositions like the CDKN2B signal, which can inform screening conversations but never replaces medical evaluation and diagnosis.

Want to understand how your metabolic and appetite pathways fit together? Take the Precision Peptide Genetic Test to understand your genetic pathway context, then bring that insight to a conversation with your provider.

This article is part of the PlexusDx Education Hub. Browse all Genetics & Metabolic Health education

The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, diagnose, or determine which peptides or treatments you should use. Consult a qualified healthcare provider before making decisions about your health or beginning any peptide protocol.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.